NGTF · Nightfood Holdings, Inc.

Nightfood Holdings' subsidiary TechForce Robotics has entered into a strategic joint development agreement with Oncotelic Therapeutics, marking an expansion into the regulated pharmaceutical manufacturing sector. The collaboration leverages Oncotelic's AI platform and pharmaceutical expertise with TechForce's robotics and hardware capabilities to develop integrated, GMP-compliant systems. The agreement establishes a comprehensive framework covering the full product lifecycle from design through commercial deployment, with both parties contributing funding and resources as outlined in written schedules. Intellectual property arrangements are clearly defined: Oncotelic retains exclusive ownership of AI-related foreground IP including improvements to its PDAOAI platform, TechForce owns robotic hardware developments, and jointly created IP is jointly owned. Financial terms for commercialization will be negotiated separately before the first commercial sale, indicating the agreement focuses primarily on development and manufacturing phases. The long-term structure with automatic five-year renewals suggests both parties anticipate sustained collaboration, while the 12-month restriction on TechForce licensing joint IP to pharmaceutical industry competitors provides Oncotelic with protection against immediate competitive threats. This agreement represents a strategic diversification for TechForce beyond its current hospitality and foodservice focus into higher-value regulated industries.